Shanghai Pharmaceuticals (02607) Proposes 2025 Interim Profit Distribution Plan

Bulletin Express

2025/10/30

Shanghai Pharmaceuticals Holding Co., Ltd. (02607) announced a proposed profit distribution for the first half of 2025, subject to shareholder approval. According to the unaudited report, the consolidated net profit attributable to shareholders amounted to RMB4,458,864,876.61. The proposed plan includes a cash dividend of RMB1.20 tax inclusive for every ten shares, based on the total share capital of 3,708,361,809 shares as of 30 June 2025. The overall cash dividend would reach RMB445,003,417.08, representing 9.98% of the net profit attributable to shareholders for the same period.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1128586489"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128586489\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128586489?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128586489","market":"us","top_or_hot":-1,"title":"Shanghai Pharmaceuticals (02607) Proposes 2025 Interim Profit Distribution Plan","media":"Bulletin Express","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (02607) announced a proposed profit distribution for the first half of 2025, subject to shareholder approval. According to the unaudited report, the consolidated net profit attributable to shareholders amounted to RMB4,458,864,876.61. The proposed plan includes a cash dividend of RMB1.20 tax inclusive for every ten shares, based on the total share capital of 3,708,361,809 shares as of 30 June 2025. The overall cash dividend would reach RMB445,003,417.08, representing 9.98% of the net profit attributable to shareholders for the same period.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals (02607) Proposes 2025 Interim Profit Distribution Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals (02607) Proposes 2025 Interim Profit Distribution Plan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-10-30 21:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (02607) announced a proposed profit distribution for the first half of 2025, subject to shareholder approval. According to the unaudited report, the consolidated net profit attributable to shareholders amounted to RMB4,458,864,876.61. The proposed plan includes a cash dividend of RMB1.20 tax inclusive for every ten shares, based on the total share capital of 3,708,361,809 shares as of 30 June 2025. The overall cash dividend would reach RMB445,003,417.08, representing 9.98% of the net profit attributable to shareholders for the same period.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02607","symbol_name":"上海醫藥","start_time":0,"source_url":"","article_id":"1128586489","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128586489","pubTimestamp":1761830411,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (02607) announced a proposed profit distribution for the first half of 2025, subject to shareholder approval. According to the unaudited report, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02607":"上海医药"},"translate_title":"上海医药(02607)提出2025年中期利润分配预案","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (02607) announced a proposed profit distribution for the first half of 2025, subject to shareholder approval. According to the unaudited report, the consolidated net profit attributable to shareholders amounted to RMB4,458,864,876.61. The proposed plan includes a cash dividend of RMB1.20 tax inclusive for every ten shares, based on the total share capital of 3,708,361,809 shares as of 30 June 2025. The overall cash dividend would reach RMB445,003,417.08, representing 9.98% of the net profit attributable to shareholders for the same period.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}